Generation of oxygen deficiency in cell culture using a two-enzyme system to evaluate agents targeting hypoxic tumor cells

Radiation Research

Volumn 170, Issue 5, 2008, Pages 651-660

  Baumann, Raymond P ^a   Penketh, Philip G ^a   Seow, Helen A ^a   Shyam, Krishnamurthy ^a   Sartorelli, Alan C ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS(METHYLSULFONYL) 1 (2 CHLOROETHYL) 2 [[1 (4 NITROPHENYL) ETHOXY] CARBONYL] HYDRAZINE; ANTINEOPLASTIC AGENT; BUFFER; CATALASE; CLORETAZINE; GLUCOSE OXIDASE; HYDROGEN PEROXIDE; KS 119; MITOMYCIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOMA CELL; CELL CULTURE; CHO CELL; CULTURE MEDIUM; DEPLETION; DRUG ACTIVATION; ENZYME ANALYSIS; GLIOMA CELL; GLUCOSE OXIDATION; HUMAN; HUMAN CELL; HYPOXIC CELL; MOLECULE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALASE; CELL HYPOXIA; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CRICETULUS; GLUCOSE; GLUCOSE OXIDASE; HUMANS; HYDRAZINES; MICE; NEOPLASMS; PRODRUGS; TUMOR CELLS, CULTURED;

CRICETULUS GRISEUS; MURINAE;

EID: 55549086157     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1431.1     Document Type: Article

References (20)

1. Q. T. Le, N. C. Denko and A. J. Giaccia, Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 23, 293-310 (2004).
2. P. W. Vaupel, S. Frinak and H. I. Bicher, Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res. 41, 2008-2013 (1981).
3. J. Pouyssegur, F. Dayan and N. M. Mazure, Hypoxia signaling in cancer and approaches to enforce tumor regression. Nature 441, 437-443 (2006).
4. Q. H. Gibson, B. E. Swoboda and V. Massay, Kinetics and mechanism of glucose oxidase. J. Biol. Chem. 11, 3927-3934 (1964).
5. S. W. Englander, D. B. Calhoun and J. J. Englander, Biochemistry without oxygen. Anal. Biochem. 161, 300-306 (1987).
6. D. Ehrismann, E. Flashman, D. N. Genn, N. Mathioudakis, K. S. Hewitson, P. J. Ratcliffe and C. J. Schofield, Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem. J. 401, 227-234 (2007).
7. H. N. Kirkman and G. F. Gaetani, Mammalian catalase: a venerable enzyme with new mysteries. Trends Biochem. Sci. 32, 44-50 (2007).
8. H. A. Seow, P. G. Penketh, K. Shyam, S. Rockwell and A. C. Sartorelli, 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl) ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells. Proc. Natl. Acad. Sci. USA 102, 9282-9287 (2005).
9. A. C. Sartorelli, Therapeutic attack of hypoxic cells of solid tumors. Cancer Res. 48, 775-778 (1988).
10. K. Shyam, P. G. Penketh, M. Shapiro, M. F. Belcourt, R. H. Loomis, S. Rockwell and A. C. Sartorelli, Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J. Med. Chem. 42, 941-946 (1999).
11. K. Shyam, P. G. Penketh, R. H. Loomis, W. C. Rose and A. C. Sartorelli, Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J. Med. Chem. 39, 796-801 (1996).
12. K. Shyam, P. G. Penketh, A. A. Divo, R. H. Loomis, C. L. Patton and A. C. Sartorelli, Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents. J. Med. Chem. 33, 2259-2264 (1990).
13. R. A. Finch, K. Shyam, P. G. Penketh and A. C. Sartorelli, 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-methyl(amino)carbonylhy drazine (101M): a novel sulfonylhydrazine prodrug with broad spectrum antineoplastic activity. Cancer Res. 61, 3033-3038 (2001).
14. F. Giles, D. Thomas, G. Garcia-Manero, S. Faderl, J. Cortes, S. Verstovsek, A. Ferrajoli, S. Jeha, M. Beran and H. Kantarjian, A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin. Cancer Res. 10, 2908-2917 (2004).
15. R. P. Baumann, H. A. Seow, K. Shyam, P. G. Penketh and A. C. Sartorelli, The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol. Res. 15, 313-325 (2005).
16. M. F. Belcourt, W. F. Hodnick, S. Rockwell and A. C. Sartorelli, The intracellular location of NADH:cytochrome b5 reductase modulates the cytotoxicity of the mitomycins to Chinese hamster ovary cells. J. Biol. Chem. 273, 8875-8881 (1998).
17. S. Rockwell, In vivo-in vitro tumor systems: new models for studying the response of tumors to therapy. Lab. Anim. Sci. 27, 831-851 (1977).
18. P. Vaupel, F. Kallinowski and P. Okunieff, Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res. 49, 6449-6465 (1989).
19. M. Höckel and P. Vaupel, Tumor hypoxia; definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93, 266-276 (2001).
20. R. E. Greenfield and V. E. Price, Liver catalase: I. A manometric determination of catalase activity. J. Biol. Chem. 209, 355-361 (1954).